Exceptional leadership and board governance are likely to expand the applications of Inmedix® CloudHRV™.
NORMANDY PARK, WA, U.S., Dec. 12, 2022 /EINPresswire.com/ — Seattle-based medical device/biotech company Inmedix, Inc., developer of immunoautonomy and cloud-based clinical diagnostics for precise quantification of stress biology, announced today the addition of Leroy Hood MD, PhD to the Board of Directors.
dr Leroy Hood, a world-renowned scientist and recipient of the 2011 National Medal of Science, co-founded the Institute for Systems Biology (ISB) in 2000, served as its first president from 2000 to 2017, and is a professor and chief strategy officer. In 2016, ISB Providence was affiliated, where Dr. Hood now serves as Science Advisor Emeritus.
He is a member of the National Academy of Sciences, the National Academy of Engineering and the National Academy of Medicine. Of the more than 6,000 scientists worldwide who belong to one or more of these academies, Dr. Hood one of only 20 people elected to all three.
He received his MD from Johns Hopkins University School of Medicine and his PhD in Biochemistry from the California Institute of Technology (Caltech). dr Hood was a faculty member at Caltech from 1967 to 1992 and served as Chair of Biology for 10 years. During this time, he and his colleagues developed four sequencer and synthesizer instruments that paved the way for the Human Genome Project’s successful mapping and understanding of the human genome. He and his students also deciphered many of the complex mechanisms of antibody diversification. In 1992, Dr. Hood the Department of Molecular Biotechnology at the University of Washington, the first academic department dedicated to interdisciplinary biology.
dr Hood has helped found 15 biotechnology companies including Amgen, Applied Biosystems, Arivale and Nanostring. He is co-author of textbooks in biochemistry, immunology, molecular biology, genetics and systems biology.
dr Hood has received numerous national and international awards, including the Lasker Award for Studies of Immune Diversity (1987), the Kyoto Prize in Advanced Technology (2002), the Heinz Award for Pioneering Work in Systems Biology (2006), the National Academy Award of Engineering Fritz J. and Delores H. Russ for the development of automated DNA sequencing (2011) and National Academy of Science for Chemistry Award in Service to Society (2017).
“I’m very interested in human well-being,” said Dr. Hood. “I have long been fascinated by heart rate variability (HRV) as a measure of evaluating a very important element of human well-being – namely stress. I believe that Inmedix will provide invaluable insights into this aspect of human well-being.”
Inmedix defines the emerging medical field of immune autonomy: the interface between immune function and stress biology, controlled in the brain by the autonomic nervous system (ANS). The natural stress response can have a short-term positive impact on immune function (1). However, chronic activation of the immune system by stress, mediated by the ANS, has been associated with adversely affecting the onset and severity of autoimmune diseases (2). With CloudHRV™ in development, Inmedix intends to provide the leading precision ANS stress state quantification tool to support research and clinical care.
“Dr. Hood has for many years been at the forefront of our appreciation of systems biology, the interconnected physiology of the human life sciences,” said Dr. holman “There is almost universal agreement that stress significantly affects health, and ANS stress status is arguably the most overlooked and potentially actionable element of personalized, accurate healthcare. I couldn’t be happier and honored to work with Dr. Hood to work together to make Inmedix a success and to uncover the fundamental genomics, epigenomics and clinical physiology of this key neuroregulatory system.”
1. Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES. The sympathetic nervous system – an integrative interface
between two supersystems: the brain and the immune system. Pharmacol. Rev. 2000;52:595-
2. Taylor PC, Holman AJ Rheumatoid arthritis and the emergence of immune autonomy.
Rheumatology (Oxford). 2019 Dec 1;58(12):2079-2080. doi: 10.1093/rheumatology/kez216. PMID:
Through Inmedix, Inc. and its subsidiary Inmedix UK, Ltd.
Seattle-based biotech/medtech company Inmedix, Inc. and its subsidiary Inmedix UK, Ltd. are committed to world-class research to find innovative solutions to urgent healthcare needs related to the effects of stress modulated in the brain by the autonomic nervous system (ANS). The Inmedix® The CloudHRV™ System is at the forefront of developing heart rate variability (HRV) as a potentially informative diagnostic, therapeutic, digital health, and health economics tool. The ANS profile is perhaps the most overlooked element of personalized precision medicine. Starting with rheumatoid arthritis (RA), psoriatic arthritis (PsA), systemic lupus erythematosus (SLE) and ankylosing spondylitis (AS) in adults, the company hopes to understand and validate the role of stress biology in immunology.
This press release contains certain forward-looking statements, including but not limited to statements regarding Inmedix’s plans for pre-clinical studies and product capabilities. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Inmedix’s business that could materially affect expected results, including, but not limited to, development progress, clinical testing and regulatory Regulatory affairs, developments in raw materials and labor costs, and statutory, tax and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and Inmedix undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release. This is neither an offer to sell nor an offer to buy any securities.
Visit http://www.inmedix.com for more information
Andrew Holman MD
email us here